These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19734632)

  • 1. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer.
    Chadha MK; Litwin A; Levea C; Iyer R; Yang G; Javle M; Gibbs JF
    JOP; 2009 Sep; 10(5):535-8. PubMed ID: 19734632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene.
    Rasmussen H; Rasmussen C; Lempicki M; Durham R; Brough D; King CR; Weichselbaum R
    Cancer Gene Ther; 2002 Nov; 9(11):951-7. PubMed ID: 12386834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenocarcinoma of the pancreas: the rationale for neoadjuvant therapy.
    Sperti C; Pasquali C; Pastorelli D; Ferronato A; Decet G; Pedrazzoli S
    Acta Biomed; 2003; 74 Suppl 2():91-5. PubMed ID: 15055044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
    Senzer N; Mani S; Rosemurgy A; Nemunaitis J; Cunningham C; Guha C; Bayol N; Gillen M; Chu K; Rasmussen C; Rasmussen H; Kufe D; Weichselbaum R; Hanna N
    J Clin Oncol; 2004 Feb; 22(4):592-601. PubMed ID: 14726502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up.
    McLoughlin JM; McCarty TM; Cunningham C; Clark V; Senzer N; Nemunaitis J; Kuhn JA
    Ann Surg Oncol; 2005 Oct; 12(10):825-30. PubMed ID: 16132372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers.
    Weichselbaum RR; Kufe D
    Cancer Gene Ther; 2009 Aug; 16(8):609-19. PubMed ID: 19444302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant therapy in pancreatic cancer].
    Ji JF; Li ZY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):644-7. PubMed ID: 16274051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant treatment for pancreatic cancer--a review.
    Tse RV; Dawson LA; Wei A; Moore M
    Crit Rev Oncol Hematol; 2008 Mar; 65(3):263-74. PubMed ID: 18063378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment.
    Mornex F; Girard N; Delpero JR; Partensky C
    Semin Radiat Oncol; 2005 Oct; 15(4):226-34. PubMed ID: 16183476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of locally advanced pancreatic cancer.
    Maheshwari V; Moser AJ
    Nat Clin Pract Gastroenterol Hepatol; 2005 Aug; 2(8):356-64. PubMed ID: 16265403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology evaluation: TNFerade, GenVec.
    Kircheis R; Wagner E
    Curr Opin Mol Ther; 2003 Aug; 5(4):437-47. PubMed ID: 14513689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer.
    Kelley JR; Fraser MM; Hubbard JM; Watson DK; Cole DJ
    Anticancer Res; 2003; 23(3A):2007-13. PubMed ID: 12894573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Up-to-date diagnosis and treatment of advanced pancreatic cancer].
    Stieler JM; Oettle H
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2146-8. PubMed ID: 16172956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of locally advanced pancreatic cancer: the role of radiation therapy.
    Johung K; Saif MW; Chang BW
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):508-18. PubMed ID: 22075449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy in pancreatic cancer.
    Quiros RM; Brown KM; Hoffman JP
    Cancer Invest; 2007 Jun; 25(4):267-73. PubMed ID: 17612937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic cancer: progress in cancer therapy.
    Pierantoni C; Pagliacci A; Scartozzi M; Berardi R; Bianconi M; Cascinu S
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):27-38. PubMed ID: 18356073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.
    Hecht JR; Farrell JJ; Senzer N; Nemunaitis J; Rosemurgy A; Chung T; Hanna N; Chang KJ; Javle M; Posner M; Waxman I; Reid A; Erickson R; Canto M; Chak A; Blatner G; Kovacevic M; Thornton M
    Gastrointest Endosc; 2012 Feb; 75(2):332-8. PubMed ID: 22248601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.